|
Sanchez Martinez I, Cerdan Sanchez M, Lopez Roman J, Iniesta Martinez F, Carreon-Guarnizo E, Meca Lallana JE, Zafrilla Rentero P. Possible Influence of the Route of Treatment Administration on Treatment Adherence in Patients With Multiple Sclerosis. Clin Ther. 2020 May;42(5):e87-e99. doi: 10.1016/j.clinthera.2020.03.005. Epub 2020 Apr 30. PubMed PMID: 32362347.
AÑO: 2020; IF: 3.393
|
|
Mutukula N, Man Z, Takahashi Y, Iniesta Martinez F, Morales M, Carreon-Guarnizo E, Hernandez Clares R, Garcia-Bernal D, Martinez Martinez L, Lajara J, Nunez Delicado E, Meca Lallana JE, Izpisua Belmonte JC. Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis. Stem Cell Res. 2021 May;53:102319. doi: 10.1016/j.scr.2021.102319. Epub 2021 Apr 15. PubMed PMID: 33894548.
AÑO: 2021; IF: 1.587
|
|
Meca-Lallana, JE; Carreon-Guarnizo, E; Hernandez-Clares, R; Gomez-Espuch, J; Diaz-Perez, J; Garcia-Molina, E; Iniesta-Martinez, F; Perez-Aranda, A; Jimenez-Veiga, J; Zamarro-Parra, J; Leon-Hernandez, A; Velazquez-Marin, F; Martin-Fernandez, JJ. Recurrent immune thrombocytopenic purpura secondary to rituximab administered as neuromyelitis optica treatment: a case report presentation. MULTIPLE SCLEROSIS JOURNAL. 2017; 23:641-641.
AÑO: 2017; IF: 5.28
|
|
Carreon Guarnizo E, Hernandez Clares R, Castillo Trivino T, Meca Lallana V, Arocas Casan V, Iniesta Martinez F, Olascoaga Urtaza J, Meca Lallana JE. Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders. Neurologia (Engl Ed). 2022 Apr;37(3):178-183. doi: 10.1016/j.nrleng.2018.12.021. Epub 2021 Feb 26. PubMed PMID: 35465911.
AÑO: 2022
|
|
Millan-Pascual J, Valero-Lopez G, Iniesta-Martinez F, Hellin-Gil MF, Jimenez-Veiga J, Lopez-Tovar IA, Morales-Ortiz A, Meca-Lallana JE. Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study. Neurol Ther. 2024 Feb;13(1):153-164. doi: 10.1007/s40120-023-00572-8. Epub 2023 Dec 14. PubMed PMID: 38097868; PubMed Central PMCID: PMC10787726.
AÑO: 2024; IF: 4.8
|